Physician profile
Sherry Lench
NPI 1144253782
$1,841.11
in general payments reported to CMS, 2019-2025
17 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $52.60 · 2021: $144 · 2022: $485 · 2023: $380 · 2024: $257 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $783.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $410.14 | 2022-2025 | Infuse, Xiidra, Biotrue |
| Maculogix, INC. | $256.82 | 2019 | |
| Coopervision INC. | $196.41 | 2019-2023 | Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $166.48 | 2021-2023 | Acuvue |
| Alcon Vision LLC | $165.14 | 2019-2023 | Total30 |
| Sun Pharmaceutical Industries INC. | $151.45 | 2019-2022 | |
| Genzyme Corporation | $124.89 | 2023 | |
| Dompe US, INC. | $106.29 | 2024 | Oxervate |
| Lkc Technologies, INC. | $90.14 | 2023 | |
| Abb Con-Cise Optical Group LLC | $36.71 | 2022 | |
| Glaxosmithkline, LLC. | $29.97 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.43 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $23.91 | 2021-2022 | |
| Optos, INC. | $16.13 | 2019 | |
| Kala Pharmaceuticals, INC. | $14.71 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $14.05 | 2019 | |
| Amgen INC. | $13.44 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Lench listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.